Population pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents
Version of Record online: 9 NOV 2011
© 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society
British Journal of Clinical Pharmacology
Volume 72, Issue 6, pages 940–947, December 2011
How to Cite
Foissac, F., Blanche, S., Dollfus, C., Hirt, D., Firtion, G., Laurent, C., Treluyer, J.-M. and Urien, S. (2011), Population pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents. British Journal of Clinical Pharmacology, 72: 940–947. doi: 10.1111/j.1365-2125.2011.04035.x
- Issue online: 9 NOV 2011
- Version of Record online: 9 NOV 2011
- Accepted manuscript online: 8 JUN 2011 01:03AM EST
- Received; 22 February 2011; Accepted; 16 May 2011; Accepted Article; 8 June 2011
- 2Food and Drug Administration (FDA). FDA Approves Atazanavir, a Once Daily Protease Inhibitor for HIV Infection. 2003. Aivailable at http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm125077.htm (last accessed 22 February 2011).
- 3European Medicines Agency (EMEA). EPAR summuray for public, Reyataz, atazanavir. 2010. Aivailable at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000494/WC500056381.pdf (last accessed 22 February 2011).
- 6Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr 2010; 53: 323–32., , , , , , , , , , , , , .
- 796-week efficacy and safety of atazanavir, with and without ritonavir, in a HAART regimen in treatment-naive patients. J Int Assoc Physicians AIDS Care (Chic Ill) 2010; 9: 34–42., , , , , , , .
- 8World Health Organization. Antiretroviral therapy for HIV infection in infants and children: towards universal access. 2010. Available at http://whqlibdoc.who.int/publications/2010/9789241599801_eng.pdf (last accessed 22 February 2011).
- 9Clinical Trials. Atazanavir used in combination with other anti-HIV drugs in HIV infected infants, children, and adolescents, no NCT00006604. 20002011. Available at http://clinicaltrials.gov/ct2/show/NCT00006604?term=1020-A&rank=1 (last accessed 22 February 2011).
- 10Food and Drug Administration. New pediatric dosing recommendations for Reyataz Capsules, patients ages 6 to 18 years old. 2009. Available at http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm121737.htm (last accessed 22 February 2011).
- 11European Medicines Agency (EMEA). EPAR summuray for public, Reyataz, atazanavir. 2006. Aivailable at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000494/WC500056377.pdf (last accessed 4 April 2011).
- 12Bristol-Myers Squibb. Reyataz™ (atazanavir sulfate) Capsules. 2003. Available at http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-567_Reyataz_Prntlbl.pdf (last accessed 22 February 2011).
- 15European Medicines Agency (EMEA). Reyataz: EPAR – product information. 2010. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000494/WC500056380.pdf (last accessed 22 February 2011).
- 16Bristol-Myers Squibb. REYATAZ: highlights of prescribing information. 2010. Available at http://packageinserts.bms.com/pi/pi_reyataz.pdf (last accessed 22 February 2011).
- 17Gilead Sciences, Inc. Viread (Tenofovir Disoproxil Fumarate) Tablet: Highlights of Prescribing Information. Foster City, CA: Gilead Sciences, Inc., 2010.
- 19NONMEM User's Guide. NONMEM project group, San Francisco, CA: University of California, 1992., .
- 23R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computin, 2009.
- 30Food and Drug Administration. New information about treatment of Latent Tuberculosis Infection in HIV infected and Uninfected Individuals. 2003. Available at http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm125074.htm (last accessed 22 February 2011).
- 31Pharmacokinetic parameters of atazanavir/ritonavir when combined to tenofovirin hiv infected patients with multiple treatment failures: a sub-study of puzzle2-ANRS 107 Trial. Conf Retroviruses Opportunistic Infect 2003; 10th: abstract no. 537., , , , , , , , .
- 32Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 2011; 1–166. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (last accessed 22 February 2011).
- 33European Medicines Agency (EMEA). Reyataz: EPAR – assesment report – variation. 2010. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000494/WC500094745.pdf (last accessed 22 February 2011).
- 34CASTLE Study: pharmacokinetics and inhibitory quotient of Atazanavir/ritonavir 300/100 mg once daily compared to Lopinavir/ritonavir 400/100 mg twice daily, each in combination with fixed dose tenofovir-emtricitabine once daily, are supportive of 48 week efficacy and safety in HIV-1 infected, treatment-naive subjects. 9th International Workshop on Pharmacology of HIV Therapy, New Orleans, LA 2008. Available at http://www.natap.org/2008/Pharm/Pharm_17.htm (last accessed 22 February 2011)., , , , , , , , , .